# Soquelitinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/soquelitinib

> The next catalyst for soquelitinib, sponsored by Corvus Pharmaceuticals, Inc. (CRVS), is its interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for soquelitinib?

The next catalyst for soquelitinib, sponsored by Corvus Pharmaceuticals, Inc. (CRVS), is its interim data readout, 1H 2027. Press release filed with the SEC (EX-99): "Initial data from the trial is anticipated in the 1H 2027." [Calendar and source filings](https://sec-api.dev/pdufa/soquelitinib)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-007175, https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/soquelitinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | soquelitinib |
| Codes | CPI-818 |
| Sponsor | Corvus Pharmaceuticals, Inc. (CRVS) https://sec-api.dev/companies/crvs/catalysts |
| Indications | [moderate to severe atopic dermatitis](https://sec-api.dev/indications/moderate-to-severe-atopic-dermatitis), [atopic dermatitis](https://sec-api.dev/indications/atopic-dermatitis), [moderate to severe hidradenitis suppurativa](https://sec-api.dev/indications/moderate-to-severe-hidradenitis-suppurativa), [asthma](https://sec-api.dev/indications/asthma), Peripheral T-Cell Lymphoma, Not Otherwise Specified |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### Apr 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: moderate to severe atopic dermatitis.
- First seen 2025-03-25, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001104659-26-123317): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-091975): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000110465926091975/crvs-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-057100): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000110465926057100/crvs-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-027047): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000110465926027047/crvs-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-106259): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000110465925106259/crvs-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010755): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000155837025010755/crvs-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006966): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000155837025006966/crvs-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003621): "In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy." https://www.sec.gov/Archives/edgar/data/1626971/000155837025003621/crvs-20241231x10k.htm

### Dec 2024: interim data readout

- Status: scheduled. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006284): "Corvus plans to announce interim data from the Phase 1 clinical trial in December 2024." https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006284): "Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024" https://www.sec.gov/Archives/edgar/data/1626971/000117184324006284/exh_991.htm

### June 5, 2025: interim data readout

- Status: scheduled. Date confidence: exact.
- First seen 2025-06-04, last confirmed 2025-06-04.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003661): "Dr. Miller will highlight the new interim data in a presentation at the Jefferies Global Healthcare Conference, which is scheduled for 9:20 am ET / 6:20 am PT on Thursday, June 5, 2025." https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/exh_991.htm

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: moderate to severe atopic dermatitis.
- First seen 2025-05-08, last confirmed 2026-03-12.
- SEC Form 8-K (accession 0001104659-26-004795): "Based on these positive results, the Company plans to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/tm263501d4_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006973): "In addition, we remain on track to initiate an atopic dermatitis Phase 2 trial with soquelitinib in early Q1 2026." https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/exh_991.htm
- SEC Form 10-K (accession 0001104659-26-027047): "Based on these positive results, we plan to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1626971/000110465926027047/crvs-20251231x10k.htm
- SEC prospectus (424B) (accession 0001104659-26-005967): "Based on these positive results, we plan to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1626971/000110465926005967/tm263501-5_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-005113): "Based on these positive results, we plan to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1626971/000110465926005113/tm263501-2_424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-006973): "On track to initiate atopic dermatitis Phase 2 clinical trial in early Q1 2026." https://www.sec.gov/Archives/edgar/data/1626971/000117184325006973/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002981): ""Looking forward, we remain on track with our key potential value-driving initiatives for soquelitinib in atopic dermatitis, including data from our new extension cohort in the fourth quarter and initiating a Phase 2 clinical trial before year-end." https://www.sec.gov/Archives/edgar/data/1626971/000117184325002981/exh_991.htm

### Mar 2026: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: atopic dermatitis.
- First seen 2026-05-07, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001104659-26-123317): "In March 2026, we initiated a Phase 2 clinical trial of soquelitinib for the treatment of atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-091975): "In March 2026, we initiated a Phase 2 clinical trial of soquelitinib for the treatment of atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1626971/000110465926091975/crvs-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-057100): "In March 2026, we initiated a Phase 2 clinical trial of soquelitinib for the treatment of atopic dermatitis." https://www.sec.gov/Archives/edgar/data/1626971/000110465926057100/crvs-20260331x10q.htm

### Sep 2026: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: moderate to severe hidradenitis suppurativa.
- First seen 2026-11-05, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001104659-26-123317): "In September 2026, we initiated a Phase 1b clinical trial with soquelitinib in patients with moderate to severe hidradenitis suppurativa." https://www.sec.gov/Archives/edgar/data/1626971/000110465926123317/crvs-20260930x10q.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007175): "Initial data from the trial is anticipated in the 1H 2027." https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007175): "Phase 1b hidradenitis suppurativa trial enrolling patients with initial data anticipated in 1H 2027; Phase 2 asthma trial to initiate by Q1 2027" https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: asthma.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007175): "Corvus plans to initiate a Phase 2 trial evaluating soquelitinib in patients with asthma, by Q1 2027." https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm

### Mar 2027: topline data readout

- Status: scheduled. Date confidence: month. Stage: 1/2.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007175): "Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2 atopic dermatitis trial; topline data anticipated in March 2027" https://www.sec.gov/Archives/edgar/data/1626971/000117184326007175/exh_991.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07441395 (Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07441395

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07441395 (Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07441395

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06561048

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06561048 (Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Corvus Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06561048

## Same indication

- [Abdakibart](https://sec-api.dev/pdufa/abdakibart) (AVTX)
- [ATI-052](https://sec-api.dev/pdufa/ati-052) (ACRS)
- [Bosakitug](https://sec-api.dev/pdufa/bosakitug) (ACRS)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Modzatinib](https://sec-api.dev/pdufa/modzatinib) (ACRS)
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [Rademikibart](https://sec-api.dev/pdufa/rademikibart) (CNTB)

Calendar months: [June 2025](https://sec-api.dev/fda-calendar/2025-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/soquelitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Soquelitinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/soquelitinib

```bibtex
@misc{secapidev_pdufa_soquelitinib_20261116,
  title        = {Soquelitinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/soquelitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_soquelitinib_20261116","title":"Soquelitinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/soquelitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
